Ascendis Pharma A/S
ASND
143 hedge funds and large institutions have $6.42B invested in Ascendis Pharma A/S in 2019 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 50 increasing their positions, 46 reducing their positions, and 14 closing their positions.
285% more call options, than puts
Call options by funds: $102M | Put options by funds: $26.4M
157% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 14
45% more capital invested
Capital invested by funds: $4.44B → $6.42B (+$1.98B)
11% more funds holding
Funds holding: 129 → 143 (+14)
7% more funds holding in top 10
Funds holding in top 10: 14 → 15 (+1)
9% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 46
0.33% less ownership
Funds ownership: 97% → 96.67% (-0.33%)
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$103M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$103M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$35.7M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
+$15.2M |
| 5 |
Bank of New York Mellon
New York
|
+$14.9M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$57.9M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$47.2M |
| 3 |
O
OrbiMed
New York
|
-$41.8M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$39.6M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$30.1M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
KAS
151
Kemnay Advisory Services
New York
| – | -$902K | -9,367 | Closed |
|
152
Simplex Trading
Chicago,
Illinois
| – | -$587K | -5,284 | Closed |
|
|
EGM
153
Engineers Gate Manager
New York
| – | -$433K | -4,491 | Closed |
|
|
DTL
154
Dynamic Technology Lab
Singapore
| – | -$430K | -4,469 | Closed |
|
|
SCM
155
Stevens Capital Management
Radnor,
Pennsylvania
| – | -$298K | -3,090 | Closed |
|
|
QT
156
Quantbot Technologies
New York
| – | -$28K | -300 | Closed |
|
|
ASN
157
Advisory Services Network
Atlanta,
Georgia
| – | -$9K | -78 | Closed |
|
ASND Hedge Fund Activity: Q4 2019 in Review
143 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Ascendis Pharma A/S (ASND) for Q4 2019, worth a combined $6.42B — up 45% from $4.44B a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new ASND positions and 14 closed out — a net gain of 22 holders — while 50 added to existing stakes and 46 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $103M. The largest seller was Millennium Management, cutting an estimated $57.9M.
- 143 institutional investors held Ascendis Pharma A/S (ASND) as of Q4 2019, up from 129 in Q3 2019.
- Funds reported $6.42B of Ascendis Pharma A/S stock for Q4 2019, up 45% quarter-over-quarter.
- 36 funds opened new Ascendis Pharma A/S positions in Q4 2019 and 14 closed out, a net change of +22 holders.
- The largest Ascendis Pharma A/S buyer in Q4 2019 was Janus Henderson Group, an estimated $103M added.
- The largest Ascendis Pharma A/S seller in Q4 2019 was Millennium Management, an estimated $57.9M sold.
Based on aggregated 13F filings for Q4 2019.